Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
Glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-dependent glucose transporter 2 inhibitor (SGLT2i), in addition to lowering glucose, have pleiotropic effects on the heart, kidneys, and liver. These drugs have thus come into widespread use for treating type 2 diabetes (T2DM). However, m...
Main Authors: | Masao Koike, Hitoki Saito, Genta Kohno, Masahiro Takubo, Kentaro Watanabe, Hisamitsu Ishihara |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/21/11463 |
Similar Items
-
High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01) -
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
by: Martina Belli, et al.
Published: (2022-11-01) -
Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Heeyoung Lee, et al.
Published: (2021-09-01) -
Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
by: Lixin Du, et al.
Published: (2022-11-01) -
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01)